SG11201408521WA - Use of ferric citrate in the treatment of chronic kidney disease patients - Google Patents
Use of ferric citrate in the treatment of chronic kidney disease patientsInfo
- Publication number
- SG11201408521WA SG11201408521WA SG11201408521WA SG11201408521WA SG11201408521WA SG 11201408521W A SG11201408521W A SG 11201408521WA SG 11201408521W A SG11201408521W A SG 11201408521WA SG 11201408521W A SG11201408521W A SG 11201408521WA SG 11201408521W A SG11201408521W A SG 11201408521WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rule
- iron
- kidney disease
- chronic kidney
- Prior art date
Links
- 208000020832 chronic kidney disease Diseases 0.000 title abstract 3
- 229960002413 ferric citrate Drugs 0.000 title abstract 3
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 title abstract 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 8
- 229910052742 iron Inorganic materials 0.000 abstract 4
- 210000002966 serum Anatomy 0.000 abstract 3
- 239000003173 antianemic agent Substances 0.000 abstract 2
- 229940125367 erythropoiesis stimulating agent Drugs 0.000 abstract 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 abstract 1
- 102000008857 Ferritin Human genes 0.000 abstract 1
- 108050000784 Ferritin Proteins 0.000 abstract 1
- 238000008416 Ferritin Methods 0.000 abstract 1
- 102000001554 Hemoglobins Human genes 0.000 abstract 1
- 108010054147 Hemoglobins Proteins 0.000 abstract 1
- 206010022971 Iron Deficiencies Diseases 0.000 abstract 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract 1
- 102000004338 Transferrin Human genes 0.000 abstract 1
- 108090000901 Transferrin Proteins 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 208000007502 anemia Diseases 0.000 abstract 1
- 229960000074 biopharmaceutical Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229910052698 phosphorus Inorganic materials 0.000 abstract 1
- 239000011574 phosphorus Substances 0.000 abstract 1
- 239000012581 transferrin Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 27 December 2013 (27.12.2013) WIPOIPCT (10) International Publication Number WO 2013/192565 A2 (51) International Patent Classification: A61K31/295 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/047134 21 June 2013 (21.06.2013) English English (30) Priority Data: 61/662,565 61/757,229 61/801,050 61/800,618 21 June 2012 (21.06.2012) US 28 January 2013 (28.01.2013) US 15 March 2013 (15.03.2013) US 15 March 2013 (15.03.2013) US (71) Applicant: KERYX BIOPHARMACEUTICALS, INC. [US/US]; 750 Lexington Avenue, 20th Floor, New York, NY 10022 (US). (72) Inventors: PORADOSU, Enrique; 42 Verndale Street, Apt. Brookline, Massachusetts 1, 02446 (US). BENTSUR, Ron; 212 Highwood Avenue, Tenafly, New Jersey 07670 (US). OLIVIERO III, James F.; 30 West Street, Apt. 32E, New York, NY 10004 (US). (74) Agents: VINNOLA, Milan M. et al.; Dorsey & Whitney LLP, 1400 Wewatta, Suite 400, Denver, Colorado 80202- 5549 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to the identity of the inventor (Rule 4.17(i)) — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — without international search report and to be republished upon receipt of that report (Rule 48.2(g)) CJ CJ o\ i-H o CJ (54) Title: USE OF FERRIC CITRATE IN THE TREATMENT OF CHRONIC KIDNEY DISEASE PATIENTS (57) Abstract: Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), in - crease hemoglobin concentration) increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron and/or reduce the need for erythropoiesis-stimulating agents (ESAs) in chronic kidney disease patients, are disclosed.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261662565P | 2012-06-21 | 2012-06-21 | |
US201361757229P | 2013-01-28 | 2013-01-28 | |
US201361800618P | 2013-03-15 | 2013-03-15 | |
US201361801050P | 2013-03-15 | 2013-03-15 | |
PCT/US2013/047134 WO2013192565A2 (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201408521WA true SG11201408521WA (en) | 2015-01-29 |
Family
ID=49769729
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201805177PA SG10201805177PA (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients |
SG11201408521WA SG11201408521WA (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201805177PA SG10201805177PA (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients |
Country Status (17)
Country | Link |
---|---|
US (3) | US20130345303A1 (en) |
EP (3) | EP2863906B1 (en) |
JP (4) | JP2015535209A (en) |
KR (2) | KR20200103855A (en) |
CN (2) | CN113244209A (en) |
AU (2) | AU2013278000A1 (en) |
BR (1) | BR112014032049A2 (en) |
CA (1) | CA2876982A1 (en) |
DK (1) | DK3730136T3 (en) |
EA (1) | EA201590062A1 (en) |
ES (2) | ES2970050T3 (en) |
HK (2) | HK1210013A1 (en) |
IL (1) | IL236356A0 (en) |
MX (1) | MX2014015615A (en) |
PL (1) | PL3730136T3 (en) |
SG (2) | SG10201805177PA (en) |
WO (1) | WO2013192565A2 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102573807A (en) | 2009-07-21 | 2012-07-11 | 凯克斯生物制药公司 | Ferric citrate dosage forms |
TWI653043B (en) * | 2012-12-20 | 2019-03-11 | 瑞士商伊蘭科動物健康公司 | New use |
DK3578185T3 (en) | 2013-06-05 | 2020-11-02 | Tricida Inc | PROTON BINDING POLYMER FOR ORAL ADMINISTRATION |
EP2856941B1 (en) * | 2013-10-01 | 2020-11-25 | Fresenius Medical Care Deutschland GmbH | Method and apparatuses for determining a patient's daily loss of iron |
JP2016535780A (en) * | 2013-11-04 | 2016-11-17 | ケリク バイオファーマシューティカルス, インコーポレーテッド | Ferric citrate to reduce heart failure in patients with chronic kidney disease |
WO2015110968A1 (en) * | 2014-01-23 | 2015-07-30 | Lupin Limited | Pharmaceutical grade ferric citrate and method for its production |
EP3157516A4 (en) | 2014-06-22 | 2017-12-13 | Dexcel Pharma Technologies Ltd. | Pharmaceutical compositions comprising ferric citrate and methods for the production thereof |
EP3593808B1 (en) | 2014-12-10 | 2020-12-09 | Tricida Inc. | Proton-binding polymers for oral administration |
KR20170123664A (en) * | 2015-03-04 | 2017-11-08 | 케릭스 바이오파마슈티컬스 인코포레이티드 | Use of citrate in the treatment of iron-deficiency anemia |
CN104688706B (en) * | 2015-04-01 | 2017-07-14 | 成都欣捷高新技术开发有限公司 | A kind of high drug load, ferrum citricum composition of Fast Stripping and preparation method thereof |
WO2016162794A1 (en) * | 2015-04-08 | 2016-10-13 | Leiutis Pharmaceuticals Pvt Ltd | Pharmaceutical compositions of ferric citrate |
WO2016162888A1 (en) * | 2015-04-09 | 2016-10-13 | Actavis Group Ptc Ehf. | Process for preparing pharmaceutical grade ferric citrate |
WO2017193024A1 (en) | 2016-05-06 | 2017-11-09 | Tricida, Inc. | Hcl-binding compositions for and method of treating acid-base disorders |
US20210085711A1 (en) | 2017-09-19 | 2021-03-25 | Japan Tobacco Inc. | Use of ferric citrate in prevention and/or treatment of iron-deficiency anemia in hypermenorrhea patient and/or patient suffering from hypermenorrhea-associated gynecologic disease |
US11266684B2 (en) | 2017-11-03 | 2022-03-08 | Tricida, Inc. | Compositions for and method of treating acid-base disorders |
WO2019236639A1 (en) * | 2018-06-04 | 2019-12-12 | Tricida, Inc. | Method of treating acid-base disorders |
BR112021008142A2 (en) * | 2018-10-29 | 2021-08-03 | Pharmacosmos Holding A/S | treatment of iron deficiency with ferric carboxymaltose |
WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
TW202313072A (en) | 2021-05-27 | 2023-04-01 | 美商凱立克斯生物製藥股份有限公司 | Pediatric formulations of ferric citrate |
CN115024495B (en) * | 2022-06-27 | 2024-03-22 | 北京金康普食品科技有限公司 | Nutritional composition for improving calcium and phosphorus metabolism of nephrosis patient and application thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998003185A1 (en) * | 1996-07-19 | 1998-01-29 | Nikken Chemicals Co., Ltd. | Remedies for hyperphosphatemia |
US5753706A (en) * | 1996-12-16 | 1998-05-19 | Hsu; Chen Hsing | Methods for treating renal failure |
TWI335218B (en) | 2003-02-19 | 2011-01-01 | Panion & Bf Biotech Inc | Ferric organic compounds, uses thereof and methods of making same |
US8093423B2 (en) | 2003-02-19 | 2012-01-10 | Globoasia, Llc | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same |
CN1600302A (en) * | 2003-09-22 | 2005-03-30 | 宝龄富锦生技股份有限公司 | Combination of medicine containing ferric citrate, medicine level ferric citrate, preparation method, and diet nutrition containing ferric citrate in medicine level |
US20060134227A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Compositions including iron |
CA3050453C (en) | 2005-08-18 | 2021-07-27 | Panion & Bf Biotech Inc. | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
KR20180077337A (en) * | 2006-01-06 | 2018-07-06 | 루이트폴드 파머수티컬스, 인코퍼레이티드 | Methods and compositions for administration of iron |
HUE028029T2 (en) | 2006-01-30 | 2016-11-28 | Panion & Bf Biotech Inc | Method of treating chronic kidney disease |
CN102573807A (en) * | 2009-07-21 | 2012-07-11 | 凯克斯生物制药公司 | Ferric citrate dosage forms |
-
2013
- 2013-06-21 US US13/924,332 patent/US20130345303A1/en not_active Abandoned
- 2013-06-21 MX MX2014015615A patent/MX2014015615A/en unknown
- 2013-06-21 KR KR1020207024260A patent/KR20200103855A/en not_active IP Right Cessation
- 2013-06-21 DK DK20163104.1T patent/DK3730136T3/en active
- 2013-06-21 CA CA2876982A patent/CA2876982A1/en not_active Abandoned
- 2013-06-21 KR KR1020157001458A patent/KR102150135B1/en active IP Right Grant
- 2013-06-21 SG SG10201805177PA patent/SG10201805177PA/en unknown
- 2013-06-21 SG SG11201408521WA patent/SG11201408521WA/en unknown
- 2013-06-21 AU AU2013278000A patent/AU2013278000A1/en not_active Abandoned
- 2013-06-21 EP EP13807102.2A patent/EP2863906B1/en active Active
- 2013-06-21 CN CN202110644193.4A patent/CN113244209A/en active Pending
- 2013-06-21 EA EA201590062A patent/EA201590062A1/en unknown
- 2013-06-21 WO PCT/US2013/047134 patent/WO2013192565A2/en active Application Filing
- 2013-06-21 EP EP23219273.2A patent/EP4335436A3/en active Pending
- 2013-06-21 ES ES20163104T patent/ES2970050T3/en active Active
- 2013-06-21 EP EP20163104.1A patent/EP3730136B1/en active Active
- 2013-06-21 JP JP2015518623A patent/JP2015535209A/en active Pending
- 2013-06-21 CN CN201380044271.0A patent/CN104884055A/en active Pending
- 2013-06-21 ES ES13807102T patent/ES2796254T3/en active Active
- 2013-06-21 PL PL20163104.1T patent/PL3730136T3/en unknown
- 2013-06-21 BR BR112014032049A patent/BR112014032049A2/en not_active IP Right Cessation
-
2014
- 2014-04-25 US US14/262,465 patent/US20140234416A1/en not_active Abandoned
- 2014-10-24 US US14/523,656 patent/US20150079168A1/en not_active Abandoned
- 2014-12-18 IL IL236356A patent/IL236356A0/en unknown
-
2015
- 2015-10-28 HK HK15110673.6A patent/HK1210013A1/en unknown
-
2016
- 2016-03-01 HK HK16102352.0A patent/HK1214503A1/en unknown
-
2018
- 2018-04-10 JP JP2018075243A patent/JP2018138562A/en active Pending
- 2018-05-08 AU AU2018203205A patent/AU2018203205B2/en not_active Ceased
-
2020
- 2020-02-25 JP JP2020029756A patent/JP2020100638A/en active Pending
-
2022
- 2022-02-10 JP JP2022019167A patent/JP2022070945A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201408521WA (en) | Use of ferric citrate in the treatment of chronic kidney disease patients | |
SG11201908391XA (en) | Methods for modulating an immune response | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
SG11201811564QA (en) | Methods of treating ovarian cancer | |
SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
SG11201804373VA (en) | Compositions and methods for immunooncology | |
SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
SG11201407669QA (en) | Methods for improving safety of blood-brain barrier transport | |
SG11201804729RA (en) | Methods and compositions for treating a serpinc1-associated disorder | |
SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
SG11201804127SA (en) | Ctla4 binders | |
SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
SG11201408124PA (en) | Differentiation of human embryonic stem cells into pancreatic endocrine cells | |
SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
SG11201407537YA (en) | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer | |
SG11201403106SA (en) | Anti-phf-tau antibodies and their uses | |
SG11201901961SA (en) | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x | |
SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
SG11201408133TA (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
SG11201807972YA (en) | Combinations of lsd1 inhibitors for the treatment of hematological malignancies | |
SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments |